Current status of immunosuppressive agents for solid organ transplantation in children

Pediatr Transplant. 2012 Mar;16(2):106-22. doi: 10.1111/j.1399-3046.2012.01644.x.

Abstract

Immunosuppression after organ transplantation is complex and ever evolving. Over the past two decades, newer immunosuppressive agents have been introduced with an aim to provide better patient and graft survival. Improved therapeutic strategies have been developed offering the option to use combinations of drugs with non-overlapping toxicities. There are, however, only a few clinical studies with robust data to rationalize the use of these agents in children. This review will discuss the newer immunosuppressive agents used for solid organ transplant, their current status in post-transplant management and prevention of allograft rejection.

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / pharmacokinetics
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antilymphocyte Serum / therapeutic use
  • Basiliximab
  • Child
  • Daclizumab
  • Everolimus
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / pharmacokinetics
  • Immunosuppressive Agents / therapeutic use*
  • Muromonab-CD3 / pharmacokinetics
  • Muromonab-CD3 / therapeutic use
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / pharmacokinetics
  • Mycophenolic Acid / therapeutic use
  • Organ Transplantation*
  • Recombinant Fusion Proteins / pharmacokinetics
  • Recombinant Fusion Proteins / therapeutic use
  • Sirolimus / analogs & derivatives
  • Sirolimus / pharmacokinetics
  • Sirolimus / therapeutic use
  • Tacrolimus / pharmacokinetics
  • Tacrolimus / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Recombinant Fusion Proteins
  • Alemtuzumab
  • Basiliximab
  • Everolimus
  • Daclizumab
  • thymoglobulin
  • Mycophenolic Acid
  • Sirolimus
  • Tacrolimus